Premium
Use of heat‐treated clotting‐factor concentrates in patients with haemophilia and a high exposure to HTLV‐III
Author(s) -
McGrath Katherine M.,
Herrington Robert W.,
Turner Peter J.,
Schiff Peter,
Thomas Kathrin B.,
Taylor Lindsay,
Ekert Henry,
Gust Ian D.
Publication year - 1985
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1985.tb122758.x
Subject(s) - clotting factor , haemophilia , fibrinogen , factor ix , antibody , medicine , haemophilia a , virus , in vivo , factor v , haemophilia b , immunology , gastroenterology , virology , surgery , biology , microbiology and biotechnology , thrombosis
In a group of 126 Australian patients with haemophilia, who were receiving lyophilized clotting‐factor concentrates prepared from locally collected plasma, a high prevalence of antibody to human T‐cell lymphotropic virus III (HTLV‐III) was demonstrated in those with severe disease. Patients with moderate or mild disease had a much lower prevalence of HTLV‐III antibody. After heat treatment of lyophilized factor VIII and factor IX concentrates (60°C for 72 hours) to inactivate the virus, the losses of activity of an intermediate‐purity and of a fibrinogen‐poor factor VIII concentrate, and of the coagulant activity of a factor IX concentrate, were within acceptable limits. The solubility of the intermediate‐purity factor VIII concentrate was markedly decreased; the fibrinogen‐poor factor VIII concentrate and the factor IX concentrate were readily soluble. In‐vivo recovery and survival of heated concentrates were equivalent to those of the unheated products, and they were effective in the treatment of spontaneous and traumatic haemorrhages.